Tharimmune, Inc. Reports Executive and Director Changes

Ticker: CNTN · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1861657

Tharimmune, INC. 8-K Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type8-K
Filed DateApr 28, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, board-of-directors, executive-appointments

TL;DR

Tharimmune board shakeup, new execs appointed.

AI Summary

On April 28, 2025, Tharimmune, Inc. filed an 8-K report detailing changes in its executive and director positions. The filing indicates the election of new directors and potential adjustments to compensatory arrangements for certain officers, though specific names and financial details were not immediately disclosed in this summary section.

Why It Matters

Changes in a company's board and executive team can signal shifts in strategy, operational focus, or financial direction.

Risk Assessment

Risk Level: medium — Changes in leadership can introduce uncertainty regarding future strategy and performance.

Key Players & Entities

FAQ

What specific changes were made to the board of directors and executive officers?

The filing indicates the election of directors and appointment of certain officers, but specific names and details are not provided in the initial summary.

Were there any changes to the company's compensatory arrangements for officers?

The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, suggesting potential changes or updates.

What is the exact date of the earliest event reported?

The earliest event reported is dated April 28, 2025.

What is Tharimmune, Inc.'s primary business sector?

Tharimmune, Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.

Where is Tharimmune, Inc.'s principal executive office located?

The principal executive offices are located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 regarding Tharimmune, Inc. (CNTN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing